Loading
Thyroid cancer that no longer takes up radioactive iodine, or keeps growing despite it. This is when kinase inhibitor pills come in.
Defined by absence of uptake on a diagnostic scan, progression within 12 months of treatment, or cumulative activity >22.2 GBq (600 mCi) without control. Affects ~5-15% of differentiated thyroid cancers, often with BRAF V600E or TERT promoter mutations. Median survival historically 3-5 years; lenvatinib, sorafenib, and genotype-directed drugs (RET, NTRK, BRAF) apply.
Showing the technology this term belongs to: Radioiodine therapy and whole-body iodine scanning.
Shares SELECT, Follicular thyroid cancer, Papillary thyroid cancer.
Shares Radioactive iodine (I-131), Radioiodine therapy and whole-body iodine scanning, Thyroid cancer.
Shares MAPK inhibitor redifferentiation → radioiodine, Radioiodine therapy and whole-body iodine scanning, Thyroid cancer.
Shares Radioactive iodine (I-131), Radioiodine therapy and whole-body iodine scanning, Thyroid cancer.
Shares DECISION, Follicular thyroid cancer.
Shares Follicular thyroid cancer, Papillary thyroid cancer, Thyroid cancer.
Shares DECISION, Thyroid cancer.